Study: Gleevec may boost efficacy of stroke therapy

06/22/2008 | Reuters

An international team of scientists who induced stroke in mice found that those that received Novartis AG's leukemia drug Gleevec experienced 33% less blood vessel leakage linked to tissue plasminogen activator, a clot-dissolving drug. The findings suggest that Gleevec may help reduce tPA-related adverse events and increase the number of patients who could receive the stroke therapy. The researchers plan to begin human trials of the drug combination in the next few months.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director Quality Improvement
Molina Healthcare of Texas
San Antonio, TX
Senior Medical Director
Network Health
Medford, MA
SVP/Head of Health Plans and Managed Care
Avalere Health
Washington, DC
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR